Molluscum Contagiosum (MC) Treatment Market Report 2026

The molluscum contagiosum (mc) treatment market size has grown strongly in recent years. It will grow from $3.1 billion in 2025 to $3.28 billion in 2026 at a compound annual growth rate (CAGR) of 5.8%. The growth in the historic period can be attributed to increasing prevalence in children, limited awareness of treatment options, reliance on self-resolving infection cycles, restricted access to dermatology care, slow adoption of prescription therapies.

The molluscum contagiosum (mc) treatment market size is expected to see strong growth in the next few years. It will grow to $4.07 billion in 2030 at a compound annual growth rate (CAGR) of 5.6%. The growth in the forecast period can be attributed to rising demand for effective topical solutions, expansion of dermatology clinics, growing preference for minimally invasive treatments, increasing product innovation, rising adoption of home-based treatments. Major trends in the forecast period include development of precision-based dermatological therapies, integration of AI-driven diagnostic support tools, adoption of digital treatment monitoring platforms, expansion of automation in dermatology product manufacturing, increasing use of virtual consultation and remote care models.

The rising demand for minimally invasive treatments is expected to drive the growth of the molluscum contagiosum treatment market in the coming years. Minimally invasive treatments are medical procedures performed with minimal damage to the body, often involving small or no incisions. Their popularity stems from benefits such as reduced recovery time, lower surgical risks, and improved patient outcomes compared to traditional procedures. Molluscum contagiosum treatments employ minimally invasive methods like cryotherapy and laser therapy to achieve effective lesion removal, faster healing, and reduced scarring. These treatments typically require fewer visits and are well-suited for managing the often widespread lesions seen in molluscum contagiosum. For example, in February 2024, according to the American Academy of Facial Plastic and Reconstructive Surgery, a US-based non-profit organization, minimally invasive procedures accounted for 83% of all medical procedures in 2023, totaling 35 million procedures, while traditional surgical procedures made up the remaining 17%. Therefore, the increasing demand for minimally invasive treatments is fueling the molluscum contagiosum treatment market.

Key companies in the molluscum contagiosum treatment market are focusing on innovative products such as topical gels to improve efficacy, patient compliance, and offer non-invasive treatment options. A topical gel is a semi-solid substance applied to the skin or mucous membranes for localized therapeutic effects. For instance, in April 2024, Ligand Pharmaceuticals Incorporated, a US-based biopharmaceutical company, launched Pelthos Therapeutics to commercialize Zelsuvmi (brazier) topical gel, 10.3%, the first FDA-approved at-home treatment for molluscum contagiosum in adults and children over one year of age. The nitric oxide-releasing gel works by disrupting viral replication, leading to lesion clearance, and offers a painless, non-invasive alternative to in-office procedures such as cryotherapy or curettage, making it practical for patients aged one and above.

In September 2023, Ligand Pharmaceuticals Incorporated, a US-based biopharmaceutical company, acquired Novan Inc. for $12.2 million. Through this acquisition, Ligand aims to preserve and expand the value of Novan’s commercial operations and Berdazimer gel development assets. Novan Inc., based in the US, specializes in treatments for molluscum contagiosum.

Major companies operating in the molluscum contagiosum (mc) treatment market are Verrica Pharmaceuticals, Novan Inc., Veloce BioPharma LLC, Polaryx Therapeutics, Aclaris Therapeutics Inc., MedCara Pharmaceuticals LLC, Pelthos Therapeutics Inc., Veradermics, Arcutis Biotherapeutics, Krystal Biotech, Connect Biopharma, AbbVie Inc., Pfizer Inc., Johnson & Johnson, Galderma S.A., LEO Pharma, Amgen, DermBiont, Almirall, Tyris Therapeutics, Abeona Therapeutics, Fibrocell Science, Amryt Pharma, Azitra.

North America was the largest region in the molluscum contagiosum (MC) treatment market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the molluscum contagiosum (mc) treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the molluscum contagiosum (mc) treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs on dermatology pharmaceuticals and medical consumables have increased procurement costs for Molluscum Contagiosum (MC) treatment products, particularly topical agents and procedural tools imported into developing regions. Hospital and clinic-based treatments are most affected due to higher volumes of regulated supplies. However, tariffs have encouraged domestic manufacturing of topical formulations, creating long-term benefits through improved local supply availability and reduced future dependency on foreign imports.

The molluscum contagiosum (mc) treatment market research report is one of a series of new reports that provides molluscum contagiosum (mc) treatment market statistics, including molluscum contagiosum (mc) treatment industry global market size, regional shares, competitors with a molluscum contagiosum (mc) treatment market share, detailed molluscum contagiosum (mc) treatment market segments, market trends and opportunities, and any further data you may need to thrive in the molluscum contagiosum (mc) treatment industry. This molluscum contagiosum (mc) treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Molluscum contagiosum (MC) treatment refers to medical interventions and strategies used to manage molluscum contagiosum, a viral skin infection caused by a poxvirus. The aim of treatment is to remove the characteristic lesions, prevent further viral spread, and relieve any associated discomfort, although the infection often resolves naturally in healthy individuals.

The main types of molluscum contagiosum treatment include molluscum contagiosum virus-1, virus-2, virus-3, and virus-4. Virus-1 is the most common subtype, responsible for 75-96% of cases, primarily affecting children through direct skin contact and causing self-limiting lesions on the face, trunk, and limbs. Treatment approaches include topical therapies, immune modulators, and procedural interventions. Medications are administered via various routes, such as topical and oral, and are utilized by hospitals, dermatology clinics, homecare providers, and other end users.

The molluscum contagiosum (MC) treatment market includes revenues earned by entities by providing services such as cryotherapy, curettage, laser therapy, and photodynamic therapy, telemedicine and online consultations. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.